ADZENYS XR-ODT Drug Patent Profile

When do Adzenys Xr-odt patents expire, and when can generic versions of Adzenys Xr-odt launch?

Adzenys Xr-odt is a drug marketed by Neos Theraps and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has two patent family members in two countries.

The generic ingredient in ADZENYS XR-ODT is amphetamine. There are fifty-five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the amphetamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adzenys Xr-odt

A generic version of ADZENYS XR-ODT was approved as amphetamine by ACTAVIS LABS FL INC on June 22^nd, 2023.

Summary for ADZENYS XR-ODT

International Patents:	2
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	28
Clinical Trials:	2
Patent Applications:	6,306
Drug Prices:	Drug price information for ADZENYS XR-ODT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADZENYS XR-ODT
What excipients (inactive ingredients) are in ADZENYS XR-ODT?	ADZENYS XR-ODT excipients list
DailyMed Link:	ADZENYS XR-ODT at DailyMed

See drug prices for ADZENYS XR-ODT

Recent Clinical Trials for ADZENYS XR-ODT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Aytu BioPharma, Inc.	PHASE4
Premier Research Group plc	PHASE4
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2

See all ADZENYS XR-ODT clinical trials

Pharmacology for ADZENYS XR-ODT

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for ADZENYS XR-ODT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ADZENYS XR-ODT	Extended-release Orally Disintegrating Tablets	amphetamine	3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg	204326	1	2016-05-10

US Patents and Regulatory Information for ADZENYS XR-ODT

ADZENYS XR-ODT is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-006	Jan 27, 2016	AB	RX	Yes	Yes	9,017,731		Y
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-006	Jan 27, 2016	AB	RX	Yes	Yes	9,265,737		Y
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-001	Jan 27, 2016	AB	RX	Yes	No	8,709,491		Y
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-004	Jan 27, 2016	AB	RX	Yes	No	9,839,619		Y
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-005	Jan 27, 2016	AB	RX	Yes	No	9,839,619		Y

Expired US Patents for ADZENYS XR-ODT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-002	Jan 27, 2016	8,840,924
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-006	Jan 27, 2016	8,840,924
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-001	Jan 27, 2016	8,840,924
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-004	Jan 27, 2016	8,840,924
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-005	Jan 27, 2016	8,840,924

International Patents for ADZENYS XR-ODT

See the table below for patents covering ADZENYS XR-ODT around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2726066	FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)
World Intellectual Property Organization (WIPO)	2013003622
European Patent Office	2726066	FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)
World Intellectual Property Organization (WIPO)	2013003622

Last updated: July 21, 2026

ADZENYS XR-ODT market dynamics and financial trajectory: revenue drivers, share, exclusivity, and generic risk

Executive summary: ADZENYS XR-ODT (amphetamine extended-release orally disintegrating tablet) competes in the US attention-deficit/hyperactivity disorder (ADHD) stimulant market where payor controls, label expansion, and formulation access drive volume. Key financial dynamics include (1) sensitivity to stimulant demand cycles and formulary restrictions, (2) ongoing pressure from alternative extended-release amphetamine and methylphenidate products, and (3) potential generic entry risk if exclusivity and patent barriers weaken. The near-term revenue path is typically shaped by payer position (preferred vs non-preferred), switchability (therapeutic equivalence and interchangeability policies), and ongoing manufacturing supply stability.

---

What is ADZENYS XR-ODT and where does it sit in the ADHD stimulant market?

ADZENYS XR-ODT is an extended-release amphetamine product in an orally disintegrating tablet (ODT) format. In the US, it targets pediatric and adult ADHD treatment, overlapping with extended-release (ER) amphetamine and ER methylphenidate regimens.

Market context that drives sales:

• ADHD stimulant demand is large, but highly competitive at the product level.
• Extended-release formulations typically gain advantage through adherence, prescriber preference, and dosing convenience.
• ODT formats can win niche share when patients have swallowing difficulty or when clinics emphasize simplified administration.

Commercial implication: ADZENYS XR-ODT’s performance depends less on “mechanism differentiation” and more on formulary positioning, substitution rules, and supply continuity.

---

How have ADHD stimulant prescribing and payer policies changed pricing power for ER amphetamine products?

Payer dynamics in ADHD:

• Managed care plans increasingly steer patients toward lower net-cost options via step edits and prior authorization.
• Formularies tend to maintain a limited set of “preferred” ER stimulants. Non-preferred products can lose volume quickly after formulary reviews.
• Pharmacy benefit managers (PBMs) use rebate and net price mechanisms to control utilization.

Impact on ADZENYS XR-ODT revenue:

• If ADZENYS XR-ODT is not preferred, growth typically depends on prescriber persistence, documented medical necessity, and patient-specific usability (ODT benefit).
• If it gains preferred status, price concessions can stabilize or increase unit share, with revenue growth following incremental utilization.

---

Which products most directly compete with ADZENYS XR-ODT in ER amphetamine and ER stimulant classes?

ADZENYS XR-ODT competes within a crowded stimulant set. The competitive set for ER amphetamine and ER stimulant switching usually includes:

ER amphetamine class substitutes (examples of overlapping prescribability):

• Mydayis (mixed amphetamine salts ER)
• Adderall XR (mixed amphetamine salts ER)
• Vyvanse (lisdexamfetamine dimesylate, ER prodrug amphetamine)

ER methylphenidate substitutes:

• Ritalin LA
• Concerta
• Jornay PM (delayed-release methylphenidate, distinct but often considered during ER planning)
• Focalin XR (dexmethylphenidate ER)

ODT and “administration convenience” competitors:

• Other convenience-driven formats (liquid, sprinkle, ODT) can pressure share for patients who cannot swallow tablets.

Commercial implication: Without a durable formulary and reimbursement advantage, ADZENYS XR-ODT faces frequent therapeutic switching even when its administration is convenient.

---

When does ADZENYS XR-ODT lose exclusivity, and what does that mean for financial trajectory?

Featured snippet answer: The primary financial inflection points for ADZENYS XR-ODT typically occur at the end of regulatory exclusivity and any expiration of relevant patents covering the ER amphetamine ODT formulation and/or method-of-use.

Why exclusivity timing matters:

• Stimulant markets can shift rapidly after generic entry, especially when PBMs re-optimize formularies and net pricing.
• Even when generics launch, revenue degradation depends on (1) how quickly prescribers switch and (2) whether pharmacists substitute under state laws and pharmacy policies.

Practical outcome for valuation and planning:

• Expect revenue compression risk to rise as near-term exclusivity windows close, unless there are defensible formulation or method patents and strong payer position.

(A complete exclusivity-and-patent timeline with specific dates requires Orange Book and patent registry data for ADZENYS XR-ODT, which is not included in the provided context.)

---

What patents protect ADZENYS XR-ODT, and how strong is the patent estate for revenue defense?

Featured snippet answer: Patent estate strength for ADZENYS XR-ODT affects generic entry risk, settlement probability, and launch timing. The strongest estates usually cover combination scope, formulation characteristics (ER/O DT-specific attributes), and manufacturing methods, along with any method-of-use protections.

How to evaluate strength for this product category:

• Count active patents listed in the Orange Book that map to the NDA for ADZENYS XR-ODT (drug substance, drug product, and method-of-use).
• Identify which patents are vulnerable to Paragraph IV challenges (if any filed), and which patents have already survived litigation or been withdrawn.

Commercial implication: For ER stimulants, narrow formulation or process patents can still matter if they block FDA approval for specific generics.

(A quantified “how many patents” and specific numbers cannot be produced without Orange Book patent listing data for ADZENYS XR-ODT.)

---

What is the Orange Book status of ADZENYS XR-ODT, and how many listings drive generic risk?

Featured snippet answer: Orange Book listings define the legally protected FDA approval basis. The number, type, and remaining lives of listed patents determine how long generics face barriers and whether Paragraph IV strategy is feasible.

How Orange Book status translates into commercial outcomes:

• More listings with later expiration typically correlate with longer disruption of generic competitive entry.
• Fewer listings or earlier expirations increase likelihood of staged market erosion (first by authorized generics or first challengers, then by broader follow-on entries).

(Orange Book listing counts and expiration dates are not available in the supplied context.)

---

Are there Paragraph IV challenges or ANDA litigation risks for ADZENYS XR-ODT?

Featured snippet answer: The presence and timing of Paragraph IV challenges are the main leading indicators of imminent price erosion for brand ER stimulants.

What drives revenue impact if challenges exist:

• Generic win outcomes typically result in faster market share transfer and net price declines via competition and rebate pressure.
• Settlements often delay entry but can shape “at-risk” launch dates and conditional market expectations.

Practical risk framing:

• Litigation calendars for stimulants can create step-function changes in expected revenue because payers and distributors pre-position inventory and contract terms.

(No specific Paragraph IV filings, docket numbers, or settlement terms are included in the provided context.)

---

Does ADZENYS XR-ODT face biosimilar risk like biologics, or only generic/authorized generic risk?

ADZENYS XR-ODT is a small-molecule stimulant product. Biosimilar pathways do not apply.

Featured snippet answer: ADZENYS XR-ODT faces generic entry risk under ANDA frameworks, not biosimilar competition.

Commercial implication:

• Competitive pressure usually begins with FDA-approved generic equivalents and authorized generics, then expands to additional manufacturers depending on interchangeability and payer contracting.

---

How do supply, manufacturing changes, and drug shortages affect ADZENYS XR-ODT revenue?

Stimulant revenue is exposed to supply disruptions and lot-level manufacturing performance.

Supply-driven dynamics:

• Any allocation or shortage increases out-of-stock risk, which depresses market share even if demand is stable.
• Conversely, improved supply stability after a disruption often unlocks “lost demand recovery,” lifting prescriptions and buy rates.

Revenue implication for planning:

• For branded ER stimulants, supply reliability can be as material as pricing, because payers and clinics may switch to alternatives quickly during stock-outs.

(No supply/lot disruption data was provided.)

---

What does the financial trajectory likely look like: growth, maturity, or decline signals in ADHD stimulants?

Financial trajectory drivers specific to this category:

• Preferred formulary status: increases stable demand and limits switching.
• Net price pressure: increases as more therapeutically equivalent choices exist or as PBM rebate structures change.
• Patient switching and prescriber behavior: can shift rapidly after competitor launches or generics enter.
• Dose mix and persistence: changes with pediatric vs adult mix, titration patterns, and adherence.

Typical lifecycle pattern for ER stimulant brands:

• Early growth phase driven by adoption, then plateau with formulary consolidation.
• Later-stage decline risks rise when generic or competitor advantage expands.

(A numeric revenue trajectory requires time-series sales or company disclosures, not provided in the prompt.)

---

Which business metrics best predict ADZENYS XR-ODT financial performance over the next 12–36 months?

High-signal indicators:

1. Net sales and unit trends by dose strength (pediatric vs adult mix).
2. Market share by class (ER amphetamine) and by format subgroup (ODT convenience).
3. Formulary position changes (preferred, tier placement, PA step edits).
4. Prescription persistence and switch rates after formulary or stock-out events.
5. Contracting outcomes with major payers and PBMs that affect net revenue.

Actionable interpretation:

• If unit share holds while net price falls, revenue may remain stable but profitability deteriorates.
• If unit share falls after formulary changes, net revenue tends to drop more sharply.

---

How does ADZENYS XR-ODT compare with competing ER stimulants on commercialization leverage?

Commercial leverage comparison framework (what usually matters):

• Administration advantage: ODT can reduce caregiver and patient friction.
• Dosing flexibility: ER stimulant dosing and titration convenience drives adherence.
• Clinical coverage: guideline and payer policies for ADHD stimulant initiation and maintenance.
• Switchability resistance: if payers require medical necessity documentation for the ODT/ER format, the brand can hold share better than a purely interchangeable tablet.

Expected competitive outcome:

• Brands with stronger payer positioning usually outperform those with comparable clinical profiles once therapeutic equivalents proliferate.

(No product-specific market share or reimbursement-position data is included in the provided context.)

---

Key Takeaways

• ADZENYS XR-ODT operates in a mature, highly competitive ADHD stimulant market where formulary placement and substitution policies often outweigh “drug differentiation.”
• The product’s financial trajectory is most sensitive to (1) payer and PBM contracting outcomes, (2) supply continuity, and (3) the timing of generic/ANDA competitive entry driven by Orange Book exclusivity and patent estate strength.
• For risk planning, the most actionable forward indicators are Orange Book listing status, any Paragraph IV litigation filings, and settlement or entry-date signals.
• Generic entry risk is the core structural threat; biosimilar dynamics do not apply to this small-molecule stimulant.

---

FAQs

1) What typically drives sudden revenue drops for ER stimulant brands in the US?
Formulary tier changes, PBM rebate re-optimization, and generic/authorized generic entry usually drive step-down revenue patterns.

2) How do PBMs influence which ER stimulant patients actually receive?
Through tier placement, prior authorization requirements, formulary exclusions, and rebate contracting that affects the net cost and preferred status of specific products.

3) Do state substitution rules matter for ADZENYS XR-ODT competing against generics?
Yes. Pharmacy substitution policies can accelerate switching once FDA-approved generic equivalents exist.

4) How do dosing-mix changes affect revenue even when total prescriptions stay flat?
Higher-priced dose strengths and shifts in pediatric versus adult utilization can materially change average selling price and net sales.

5) What should stakeholders monitor to anticipate generic entry risk for ADZENYS XR-ODT?
Orange Book patent expiration dates, the presence of Paragraph IV challenges, and public litigation or settlement activity that signals launch windows.

---

References

No sources were provided in the prompt, and no Orange Book, FDA, or litigation records were included to support a fact-based, date-specific exclusivity and financial trajectory analysis.